G. Koev

发表

The emerging field of HCV drug resistance

W. Kati, G. Koev, 2008 .

Are There Risks Associated with Transgenic Resistance to Luteoviruses?

W. Miller, B. R. Mohan, G. Koev, 1997, Plant disease.

Original Article Protein and mRNA Levels of YKL-40 in High-Grade Glioma

N. Mateva, M. Kazakova, V. Sarafian, 2014 .

Exploratory study of oral combination antiviral therapy for hepatitis C.

T. Pilot‐Matias, K. Kowdley, D. Cohen, 2013, The New England journal of medicine.

In Vitro and In Vivo Antiviral Activity and Resistance Profile of Ombitasvir , an Inhibitor of Hepatitis C Virus NS 5 A

A. Molla, T. Pilot‐Matias, T. Reisch, 2015 .

In Vitro and In Vivo Antiviral Activity and Resistance Profile of Ombitasvir, an Inhibitor of Hepatitis C Virus NS5A

A. Molla, T. Pilot‐Matias, T. Reisch, 2014, Antimicrobial Agents and Chemotherapy.

Aryl uracil inhibitors of hepatitis C virus NS5B polymerase: synthesis and characterization of analogs with a fused 5,6-bicyclic ring motif.

K. Longenecker, A. C. Krueger, A. Molla, 2013, Bioorganic & medicinal chemistry letters.

In Vitro Activity and Resistance Profile of Dasabuvir, a Nonnucleoside Hepatitis C Virus Polymerase Inhibitor

A. Molla, T. Reisch, W. Kati, 2014, Antimicrobial Agents and Chemotherapy.

867 IN VITRO COMBINATORY EFFECT OF HCV NS3/4A PROTEASE INHIBITOR ABT-450, NS5A INHIBITOR ABT-267, AND NON-NUCLEOSIDE NS5B POLYMERASE INHIBITOR ABT-333

A. Molla, Liangjun Lu, T. Pilot‐Matias, 2012 .

Des-A-ring benzothiadiazines: inhibitors of HCV genotype 1 NS5B RNA-dependent RNA polymerase.

A. Molla, D. Kempf, W. Kati, 2008, Bioorganic & medicinal chemistry letters.

Methods to measure the intracellular concentration of unlabeled compounds within cultured cells using liquid chromatography/tandem mass spectrometry.

P. Richardson, W. Kati, C. Chen, 2008, Analytical biochemistry.

Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.

A. C. Krueger, A. Molla, T. Pilot‐Matias, 2014, Journal of medicinal chemistry.

955 PRECLINICAL POTENCY, PHARMACOKINETIC AND ADME CHARACTERIZATION OF ABT-333, A NOVEL NON-NUCLEOSIDE HCV POLYMERASE INHIBITOR

A. Molla, D. Beno, C. Flentge, 2009 .

Inhibitors of hepatitis C virus polymerase: synthesis and biological characterization of unsymmetrical dialkyl-hydroxynaphthalenoyl-benzothiadiazines.

A. C. Krueger, A. Molla, D. Kempf, 2009, Journal of medicinal chemistry.

Hepatitis C NS5B polymerase inhibitors: functional equivalents for the benzothiadiazine moiety.

V. Stoll, A. Molla, D. Kempf, 2011, Bioorganic & medicinal chemistry letters.

Synthesis and biological characterization of B-ring amino analogues of potent benzothiadiazine hepatitis C virus polymerase inhibitors.

A. Molla, D. Kempf, J. Randolph, 2009, Journal of medicinal chemistry.

Mutations Conferring Resistance to a Hepatitis C Virus (HCV) RNA-Dependent RNA Polymerase Inhibitor Alone or in Combination with an HCV Serine Protease Inhibitor In Vitro

Kent D. Stewart, Teresa Ng, Rubina Mondal, 2005, Antimicrobial Agents and Chemotherapy.

Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology

A. Molla, H. Mo, T. Pilot‐Matias, 2007, Hepatology.

Development of a cell-based assay for high-throughput screening of inhibitors against HCV genotypes 1a and 1b in a single well.

A. Molla, T. Pilot‐Matias, W. Kati, 2009, Antiviral research.

A replicon-based shuttle vector system for assessing the phenotype of HCV NS5B polymerase genes isolated from patient populations.

A. Molla, H. Mo, T. Pilot‐Matias, 2007, Journal of virological methods.

A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1.

T. Pilot‐Matias, K. Kowdley, D. Cohen, 2013, Journal of hepatology.

Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro.

H. Mo, T. Pilot‐Matias, K. Stewart, 2007, Antiviral research.

Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro.

A. Molla, H. Mo, T. Ng, 2007, Antiviral research.

Hepatitis C virus IRES-dependent translation is insensitive to an eIF2alpha-independent mechanism of inhibition by interferon in hepatocyte cell lines.

M. Lai, R. Duncan, G. Koev, 2002, Virology.

The emerging field of HCV drug resistance.

W. Kati, G. Koev, 2008, Expert opinion on investigational drugs.

In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 2 with Decreased Susceptibility to Lopinavir

F. Gao, A. Molla, D. Kempf, 2007, Antimicrobial Agents and Chemotherapy.

In Vitro Selection and Characterization of Human Immunodeﬁciency Virus Type 2 with Decreased Susceptibility to Lopinavir (cid:1)

A. Molla, D. Kempf, H. Mo, 2007 .

Synthesis of subgenomic RNAs by positive-strand RNA viruses.

W. Miller, G. Koev, 2000, Virology.

Synthesis and SAR of novel 1,1-dialkyl-2(1H)-naphthalenones as potent HCV polymerase inhibitors.

A. Molla, D. Kempf, H. Mo, 2008, Bioorganic & medicinal chemistry letters.

Primary and Secondary Structural Elements Required for Synthesis of Barley Yellow Dwarf Virus Subgenomic RNA1

W. Miller, B. R. Mohan, G. Koev, 1999, Journal of Virology.

Primary and Secondary Structural Elements Required for Synthesis of Barley Yellow Dwarf Virus Subgenomic RNA 1 †

W. Miller, B. R. Mohan, G. Koev, 1999 .

MINIREVIEW Synthesis of Subgenomic RNAs by Positive-Strand RNA Viruses

W. Miller, G. Koev, 2000 .

A Positive-Strand RNA Virus with Three Very Different Subgenomic RNA Promoters

W. Miller, G. Koev, 2000, Journal of Virology.

The 3′-Terminal Structure Required for Replication of Barley Yellow Dwarf Virus RNA Contains an Embedded 3′ End

W. Allen Miller, W. Miller, Gennadiy Koev, 2002 .

The 3 9-Terminal Structure Required for Replication of Barley Yellow Dwarf Virus RNA Contains an Embedded 3 9 End

W. Miller, Randy J. Beckett, Sijun Liu, 2002 .

1206 ABT-072 OR ABT-333 COMBINED WITH PEGYLATED INTERFERON/RIBAVIRIN AFTER 3-DAY MONOTHERAPY IN HCV GENOTYPE 1 (GT1)-INFECTED TREATMENT-NAIVE SUBJECTS: 12-WEEK SUSTAINED VIROLOGIC RESPONSE (SVR12) AND SAFETY RESULTS

T. Pilot‐Matias, K. Kowdley, W. Xie, 2012 .

Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery of ABT-072, a trans-Stilbene Analog with Good Oral Bioavailability.

K. Longenecker, A. C. Krueger, A. Molla, 2018, Journal of medicinal chemistry.

A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1.

K. Kowdley, D. Cohen, E. Lawitz, 2013, Journal of hepatology.

Interferon-Free Regimens for Chronic Hepatitis C—A Step Forward

E. Lawitz, F. Poordad, T. Podsadecki, 2013 .